| Identification | Back Directory | [Name]
1-(3-(tert-butyl)-1'-(2-(dimethylamino)ethyl)-1'H-[1,4'-bipyrazol]-5-yl)- 3-((1S,4R)-4-((3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)oxy)- 1,2,3,4-tetrahydronaphthalen-1-yl)urea | [CAS]
1443242-46-3 | [Synonyms]
p38-α MAPK-IN-5
1-(3-(tert-butyl)-1'-(2-(dimethylamino)ethyl)-1'H-[1,4'-bipyrazol]-5-yl)- 3-((1S,4R)-4-((3-((S)-2-methylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)oxy)- 1,2,3,4-tetrahydronaphthalen-1-yl)urea | [EINECS(EC#)]
813-863-0 | [Molecular Formula]
C37H49N11O2 | [MOL File]
1443242-46-3.mol | [Molecular Weight]
679.857 |
| Hazard Information | Back Directory | [Uses]
p38-α MAPK-IN-5 (compound 4e) is a potent p38α inhibitor with IC50s of 0.1 nM, 0.2 nM, 944 nM, 4100 nM for p38α, p38 β, p38γ, p38δ, respectively. p38-α MAPK-IN-5 has anti-inflammatory effect. p38-α MAPK-IN-5 has the potential for asthma and chronic obstructive pulmonary disease (COPD) research[1]. | [IC 50]
p38α: 0.1 nM (IC50); p38β: 0.2 nM (IC50); p38γ: 944 nM (IC50); p38δ: 4100 nM (IC50) | [References]
[1] Elisabetta Armani, et al. Design, Synthesis, and Biological Characterization of Inhaled p38α/β MAPK Inhibitors for the Treatment of Lung Inflammatory Diseases. J Med Chem. 2022 May 26;65(10):7170-7192. DOI:10.1021/acs.jmedchem.2c00115 |
|
|